Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1024 participants
INTERVENTIONAL
2004-05-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To evaluate change in total volume of all nodules.
Secondary objectives:
* To evaluate change in goiter volume after a 12-months treatment, number of nodules and echogenicity of nodules.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Levothyroxine-Na + iodide
1 tablet 30 minutes before breakfast
2
Levothyroxin-Na
1 tablet 30 minutes before breakfast
3
Iodide
1 tablet 30 minutes before breakfast
4
Placebo
1 tablet 30 minutes before breakfast
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levothyroxin-Na
1 tablet 30 minutes before breakfast
Levothyroxine-Na + iodide
1 tablet 30 minutes before breakfast
Iodide
1 tablet 30 minutes before breakfast
Placebo
1 tablet 30 minutes before breakfast
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal TSH value (target range between 0.6 - 3.0 mU/l)
* Thyroid nodules in a normal sized or enlarged thyroid at least one nodule (smaller/equal 20 % of volume with cystic change) with greater/equal 1.0 cm diameter, for nodules greater 1.0 cm the diagnosis must be performed according to the guideline for diagnostic standards of thyroid disorders.
Exclusion Criteria
* Known focal or diffuse structure autonomous thyroid
* Contraindication to iodine
* Concomitant treatment with iodine containing medication (i.e. amiodarone)
* Use of iodine-containing contrast medium within the last 6 weeks
* Presence of TPO antibodies (maximum two fold normal value)
* Symptomatic coronary heart disease
* Endocrine orbitopathy
* Known autoimmune thyreopathy
* Former radioiodine therapy or surgery
* Dermatitis herpetiformis
* Pathological laboratory results
* Participation in another clinical study with investigational medication within the last 30 days
* Pregnant or nursing female patients
* Female patients of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, unless they are surgically sterilized/hysterectomized or who are not using any other method considered sufficiently reliable by the investigator in individual cases.
* Severe or unstable cardiovascular diseases (e.g. severe angina pectoris, postmyocardial infarction syndrome and ventricular extrasystoles, symptomatic coronary heart disease), clinically relevant renal or hepatic diseases or disorders, any other clinically relevant condition that might enhance the risk for the study participant.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katrin Roscher
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sanofi-Aventis Administrative Office
Frankfurt, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
L_9133
Identifier Type: -
Identifier Source: org_study_id